Neuroprotection of Erythropoietin and Methylprednisolone against Spinal Cord Ischemia-Reperfusion Injury
Recent research based on various animal models has shown the neuroprotective effects of erythropoietin （EPO）. However, few studies have examined such effects of EPO in the clinic. In this study we enrolled patients with spinal cord ischemia-reperfusion （I-R） injury to investigate the clinical applic...
Saved in:
| Published in | Journal of Huazhong University of Science and Technology. Medical sciences Vol. 31; no. 5; pp. 652 - 656 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | English |
| Published |
Heidelberg
Huazhong University of Science and Technology
01.10.2011
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1672-0733 1993-1352 |
| DOI | 10.1007/s11596-011-0576-z |
Cover
| Abstract | Recent research based on various animal models has shown the neuroprotective effects of erythropoietin （EPO）. However, few studies have examined such effects of EPO in the clinic. In this study we enrolled patients with spinal cord ischemia-reperfusion （I-R） injury to investigate the clinical application of EPO and methylprednisolone （MP） for the neuroprotection against spinal cord I-R injury. Retrospective analysis of 63 cases of spinal cord I-R injury was performed. The Frankel neurological performance scale was used to evaluate the neurological function after spinal cord injury （SCI）, including 12 cases of scale B, 30 cases of scale C, and 21 cases of scale D. These cases were divided into 2 groups： group A （27 cases） got treatment with both EPO and MP; group B （36 cases） got treatment with MP only. The neurological function of patients after treatment was evaluated by American Spinal Cord Injury Association （ASIA） index score, and activity of daily living （ADL） of the patients was also recorded. All patients got follow-up and the follow-up period ranged from 24 to 39 months （mean 26 months）. There was no significance difference in neurological function between groups A and B before the treatment （P〉0.05）. However, the neurological function and ADL scores were significantly improved 1 week, 1 year or 2 years after the treatment compared to those before the treatment （P〈0.05）, and the improvement was more significant in group A than in group B （P〈0.05）. It is suggested that the clinical application of EPO and MP provides the neuroprotection against spinal cord I-R injury. |
|---|---|
| AbstractList | Recent research based on various animal models has shown the neuroprotective effects of erythropoietin (EPO). However, few studies have examined such effects of EPO in the clinic. In this study we enrolled patients with spinal cord ischemia-reperfusion (I-R) injury to investigate the clinical application of EPO and methylprednisolone (MP) for the neuroprotection against spinal cord I-R injury. Retrospective analysis of 63 cases of spinal cord I-R injury was performed. The Frankel neurological performance scale was used to evaluate the neurological function after spinal cord injury (SCI), including 12 cases of scale B, 30 cases of scale C, and 21 cases of scale D. These cases were divided into 2 groups: group A (27 cases) got treatment with both EPO and MP; group B (36 cases) got treatment with MP only. The neurological function of patients after treatment was evaluated by American Spinal Cord Injury Association (ASIA) index score, and activity of daily living (ADL) of the patients was also recorded. All patients got follow-up and the follow-up period ranged from 24 to 39 months (mean 26 months). There was no significance difference in neurological function between groups A and B before the treatment (P>0.05). However, the neurological function and ADL scores were significantly improved 1 week, 1 year or 2 years after the treatment compared to those before the treatment (P<0.05), and the improvement was more significant in group A than in group B (P<0.05). It is suggested that the clinical application of EPO and MP provides the neuroprotection against spinal cord I-R injury. Recent research based on various animal models has shown the neuroprotective effects of erythropoietin (EPO). However, few studies have examined such effects of EPO in the clinic. In this study we enrolled patients with spinal cord ischemia-reperfusion (I-R) injury to investigate the clinical application of EPO and methylprednisolone (MP) for the neuroprotection against spinal cord I-R injury. Retrospective analysis of 63 cases of spinal cord I-R injury was performed. The Frankel neurological performance scale was used to evaluate the neurological function after spinal cord injury (SCI), including 12 cases of scale B, 30 cases of scale C, and 21 cases of scale D. These cases were divided into 2 groups: group A (27 cases) got treatment with both EPO and MP; group B (36 cases) got treatment with MP only. The neurological function of patients after treatment was evaluated by American Spinal Cord Injury Association (ASIA) index score, and activity of daily living (ADL) of the patients was also recorded. All patients got follow-up and the follow-up period ranged from 24 to 39 months (mean 26 months). There was no significance difference in neurological function between groups A and B before the treatment (P>0.05). However, the neurological function and ADL scores were significantly improved 1 week, 1 year or 2 years after the treatment compared to those before the treatment (P<0.05), and the improvement was more significant in group A than in group B (P<0.05). It is suggested that the clinical application of EPO and MP provides the neuroprotection against spinal cord I-R injury.Recent research based on various animal models has shown the neuroprotective effects of erythropoietin (EPO). However, few studies have examined such effects of EPO in the clinic. In this study we enrolled patients with spinal cord ischemia-reperfusion (I-R) injury to investigate the clinical application of EPO and methylprednisolone (MP) for the neuroprotection against spinal cord I-R injury. Retrospective analysis of 63 cases of spinal cord I-R injury was performed. The Frankel neurological performance scale was used to evaluate the neurological function after spinal cord injury (SCI), including 12 cases of scale B, 30 cases of scale C, and 21 cases of scale D. These cases were divided into 2 groups: group A (27 cases) got treatment with both EPO and MP; group B (36 cases) got treatment with MP only. The neurological function of patients after treatment was evaluated by American Spinal Cord Injury Association (ASIA) index score, and activity of daily living (ADL) of the patients was also recorded. All patients got follow-up and the follow-up period ranged from 24 to 39 months (mean 26 months). There was no significance difference in neurological function between groups A and B before the treatment (P>0.05). However, the neurological function and ADL scores were significantly improved 1 week, 1 year or 2 years after the treatment compared to those before the treatment (P<0.05), and the improvement was more significant in group A than in group B (P<0.05). It is suggested that the clinical application of EPO and MP provides the neuroprotection against spinal cord I-R injury. Recent research based on various animal models has shown the neuroprotective effects of erythropoietin （EPO）. However, few studies have examined such effects of EPO in the clinic. In this study we enrolled patients with spinal cord ischemia-reperfusion （I-R） injury to investigate the clinical application of EPO and methylprednisolone （MP） for the neuroprotection against spinal cord I-R injury. Retrospective analysis of 63 cases of spinal cord I-R injury was performed. The Frankel neurological performance scale was used to evaluate the neurological function after spinal cord injury （SCI）, including 12 cases of scale B, 30 cases of scale C, and 21 cases of scale D. These cases were divided into 2 groups： group A （27 cases） got treatment with both EPO and MP; group B （36 cases） got treatment with MP only. The neurological function of patients after treatment was evaluated by American Spinal Cord Injury Association （ASIA） index score, and activity of daily living （ADL） of the patients was also recorded. All patients got follow-up and the follow-up period ranged from 24 to 39 months （mean 26 months）. There was no significance difference in neurological function between groups A and B before the treatment （P〉0.05）. However, the neurological function and ADL scores were significantly improved 1 week, 1 year or 2 years after the treatment compared to those before the treatment （P〈0.05）, and the improvement was more significant in group A than in group B （P〈0.05）. It is suggested that the clinical application of EPO and MP provides the neuroprotection against spinal cord I-R injury. Summary Recent research based on various animal models has shown the neuroprotective effects of erythropoietin (EPO). However, few studies have examined such effects of EPO in the clinic. In this study we enrolled patients with spinal cord ischemia-reperfusion (I-R) injury to investigate the clinical application of EPO and methylprednisolone (MP) for the neuroprotection against spinal cord I-R injury. Retrospective analysis of 63 cases of spinal cord I-R injury was performed. The Frankel neurological performance scale was used to evaluate the neurological function after spinal cord injury (SCI), including 12 cases of scale B, 30 cases of scale C, and 21 cases of scale D. These cases were divided into 2 groups: group A (27 cases) got treatment with both EPO and MP; group B (36 cases) got treatment with MP only. The neurological function of patients after treatment was evaluated by American Spinal Cord Injury Association (ASIA) index score, and activity of daily living (ADL) of the patients was also recorded. All patients got follow-up and the follow-up period ranged from 24 to 39 months (mean 26 months). There was no significance difference in neurological function between groups A and B before the treatment ( P >0.05). However, the neurological function and ADL scores were significantly improved 1 week, 1 year or 2 years after the treatment compared to those before the treatment ( P <0.05), and the improvement was more significant in group A than in group B ( P <0.05). It is suggested that the clinical application of EPO and MP provides the neuroprotection against spinal cord I-R injury. |
| Author | 熊敏 陈森 余化龙 刘志刚 曾云 李锋 |
| AuthorAffiliation | Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China Department of Spinal Surgery, Dongfeng General Hospital, Hubei University of Medicine, Shiyan 442008, China |
| Author_xml | – sequence: 1 fullname: 熊敏 陈森 余化龙 刘志刚 曾云 李锋 |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22038355$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kUtv3CAUhVGVqnm0P6Cbyl21GydcYxuzrEZpM1LaSH2sEcbXY0YecAAvJr8-WDPJootZgdB37rmcc0nOrLNIyEeg10ApvwkAlahzCpDTitf50xtyAUKwHFhVnKV7zYuccsbOyWUIW7pARfmOnBcFZQ2rqgsy_MLZu8m7iDoaZzPXZ7d-H4f06AxGYzNlu-wnxmE_Th47a4Ib0xqZ2ihjQ8z-TMaqMVs532XroAfcGZX_xgl9P4dl4tpuZ79_T972agz44XhekX_fb_-u7vL7hx_r1bf7XJe0iDmqFtoeuBaci443nYZWadFh2YqWgcCqQeRt1SjsWxBNrbEWXaloq6FE1bEr8uUwN_3pccYQ5c4EjeOoLLo5SEGB0SZFlsivJ0komoqKFGWT0E9HdG532MnJm53ye_mSYwLgAGjvQvDYvyJA5dKVPHQlk7FcapBPScP_02gT1VJC9MqMJ5XFQRmSi92gl1s3-9RCOCn6fLQbnN08Jt3rjiUFXtO6YM__0rby |
| CitedBy_id | crossref_primary_10_3892_etm_2017_4182 crossref_primary_10_3892_ijmm_2014_1644 crossref_primary_10_4103_1673_5374_235012 crossref_primary_10_3233_RNN_150498 crossref_primary_10_1016_j_rbo_2014_09_014 crossref_primary_10_3892_ijmm_2015_2344 crossref_primary_10_1007_s12035_020_01997_0 crossref_primary_10_1053_j_jvca_2016_01_006 crossref_primary_10_1038_s41393_020_00604_2 crossref_primary_10_3390_ijms18020466 crossref_primary_10_1002_advs_201800529 crossref_primary_10_1007_s00586_025_08687_2 crossref_primary_10_1016_j_rboe_2015_09_001 crossref_primary_10_1007_s10856_016_5714_5 crossref_primary_10_1016_j_brainres_2012_06_055 |
| Cites_doi | 10.1111/j.1471-4159.2005.03597.x 10.1016/j.expneurol.2007.12.013 10.1358/dnp.2007.20.5.1120219 10.1038/sc.1994.92 10.1016/j.neuroscience.2007.11.004 10.3345/kjp.2010.53.10.898 10.4161/oxim.2.5.9990 10.1097/00007632-199603010-00015 10.1007/s00402-008-0594-x 10.1016/j.neuroscience.2006.10.023 10.1016/j.jocn.2006.01.022 10.1007/s00586-008-0829-0 10.1073/pnas.0508479102 10.1016/j.neulet.2006.11.015 |
| ContentType | Journal Article |
| Copyright | Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2011 |
| Copyright_xml | – notice: Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2011 |
| DBID | 2RA 92L CQIGP W91 ~WA AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TK 7X8 |
| DOI | 10.1007/s11596-011-0576-z |
| DatabaseName | 维普期刊资源整合服务平台 中文科技期刊数据库-CALIS站点 中文科技期刊数据库-7.0平台 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Neurosciences Abstracts MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Neurosciences Abstracts MEDLINE - Academic |
| DatabaseTitleList | Neurosciences Abstracts MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Neuroprotection of Erythropoietin and Methylprednisolone against Spinal Cord Ischemia-Reperfusion Injury |
| EISSN | 1993-1352 |
| EndPage | 656 |
| ExternalDocumentID | 22038355 10_1007_s11596_011_0576_z 40176062 |
| Genre | Journal Article |
| GroupedDBID | -5E -5G -BR -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 1N0 29K 29~ 2B. 2C~ 2J2 2KG 2KM 2LR 2RA 2~H 30V 4.4 408 40D 40E 53G 5GY 5VS 6NX 8TC 8UJ 92F 92I 92L 95- 95. 95~ 96X AAAVM AABHQ AAJKR AANXM AARHV AARTL AAYIU AAYQN AAYTO ABFTV ABJNI ABJOX ABKCH ABMNI ABNWP ABQBU ABTMW ACGFS ACHXU ACKNC ACOMO ACSNA ACUDM ADHIR ADINQ ADKPE ADURQ ADYFF ADZKW AEBTG AEGNC AEJHL AEKMD AEOHA AEPYU AETLH AEXYK AFWTZ AFZKB AGAYW AGDGC AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHKAY AHYZX AIIXL AJBLW AJRNO ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP ARMRJ AZFZN B-. BA0 BGNMA CAG CCEZO CHBEP CIEJG COF CQIGP CS3 CSCUP CW9 D-I DPUIP EBS EJD ESBYG FA0 FEDTE FNLPD FRRFC FWDCC G-Y G-Z GGCAI GGRSB GJIRD GQ6 GQ7 HF~ HG6 HMJXF HRMNR HVGLF HZ~ IJ- IXD I~X I~Z J-C JBSCW JUIAU KOV M4Y MA- N2Q NDZJH NQJWS NU0 O9- O93 O9I O9J P9S PF0 QOR QOS R-E R89 R9I RIG ROL RPX RSV S.. S16 S1Z S27 S37 S3B SAP SCL SDH SHX SMD SNE SNX SOJ SPISZ SZ9 SZN T13 TCJ TSG TT1 TUC U2A U9L UG4 VC2 W48 W91 WK8 Z7U Z82 Z8V ZOVNA ~A9 ~WA ABQSL H13 AAYXX ADHKG AGQPQ CITATION CGR CUY CVF ECM EIF NPM 7TK 7X8 |
| ID | FETCH-LOGICAL-c402t-eab1bf17c9779d78dc1bac9de4b9b319e58ee7b58aefb1986ce69d4a0bc14ead3 |
| IEDL.DBID | AGYKE |
| ISSN | 1672-0733 |
| IngestDate | Fri Sep 05 03:20:53 EDT 2025 Sun Aug 24 03:58:54 EDT 2025 Thu Jan 02 23:11:22 EST 2025 Thu Apr 24 22:56:53 EDT 2025 Wed Oct 01 00:35:55 EDT 2025 Fri Feb 21 02:37:18 EST 2025 Wed Feb 14 10:48:16 EST 2024 |
| IsPeerReviewed | false |
| IsScholarly | false |
| Issue | 5 |
| Keywords | ischemia-reperfusion injury methylprednisolone spinal cord neuroprotection erythropoietin |
| Language | English |
| License | http://www.springer.com/tdm |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c402t-eab1bf17c9779d78dc1bac9de4b9b319e58ee7b58aefb1986ce69d4a0bc14ead3 |
| Notes | erythropoietin methylprednisolone neuroprotection spinal cord ischemia-reperfusion in-jury Recent research based on various animal models has shown the neuroprotective effects of erythropoietin （EPO）. However, few studies have examined such effects of EPO in the clinic. In this study we enrolled patients with spinal cord ischemia-reperfusion （I-R） injury to investigate the clinical application of EPO and methylprednisolone （MP） for the neuroprotection against spinal cord I-R injury. Retrospective analysis of 63 cases of spinal cord I-R injury was performed. The Frankel neurological performance scale was used to evaluate the neurological function after spinal cord injury （SCI）, including 12 cases of scale B, 30 cases of scale C, and 21 cases of scale D. These cases were divided into 2 groups： group A （27 cases） got treatment with both EPO and MP; group B （36 cases） got treatment with MP only. The neurological function of patients after treatment was evaluated by American Spinal Cord Injury Association （ASIA） index score, and activity of daily living （ADL） of the patients was also recorded. All patients got follow-up and the follow-up period ranged from 24 to 39 months （mean 26 months）. There was no significance difference in neurological function between groups A and B before the treatment （P〉0.05）. However, the neurological function and ADL scores were significantly improved 1 week, 1 year or 2 years after the treatment compared to those before the treatment （P〈0.05）, and the improvement was more significant in group A than in group B （P〈0.05）. It is suggested that the clinical application of EPO and MP provides the neuroprotection against spinal cord I-R injury. 42-1679/R ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
| PMID | 22038355 |
| PQID | 1285091358 |
| PQPubID | 23462 |
| PageCount | 5 |
| ParticipantIDs | proquest_miscellaneous_901308011 proquest_miscellaneous_1285091358 pubmed_primary_22038355 crossref_primary_10_1007_s11596_011_0576_z crossref_citationtrail_10_1007_s11596_011_0576_z springer_journals_10_1007_s11596_011_0576_z chongqing_primary_40176062 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2011-10-01 |
| PublicationDateYYYYMMDD | 2011-10-01 |
| PublicationDate_xml | – month: 10 year: 2011 text: 2011-10-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Heidelberg |
| PublicationPlace_xml | – name: Heidelberg – name: China |
| PublicationSubtitle | Medical Sciences |
| PublicationTitle | Journal of Huazhong University of Science and Technology. Medical sciences |
| PublicationTitleAbbrev | J. Huazhong Univ. Sci. Technol. [Med. Sci.] |
| PublicationTitleAlternate | Journal of Zuazhong University of Science and Technology： Medical Edition |
| PublicationYear | 2011 |
| Publisher | Huazhong University of Science and Technology |
| Publisher_xml | – name: Huazhong University of Science and Technology |
| References | Fang, Fang, Fan (CR11) 2009; 122 Grasso, Sfacteria, Meli (CR5) 2007; 20 Vitellaro-Zuccarello, Mazzetti, Madaschi (CR8) 2007; 144 Matis, Birbilis (CR12) 2009; 18 EI Masry, Tsubo, Katoh (CR4) 1996; 21 Choi, Ha, Ahn (CR7) 2007; 412 Xiong, Chen, Zeng (CR17) 2011; 28 Mann, Lee, Liu (CR9) 2008; 211 Kim, Seo, Park (CR15) 2010; 53 Dame, Juul, Christensen (CR1) 2001; 79 Kontogeorgakos, Voulgaris, Korompilias (CR13) 2009; 129 Maiese, Chong, Hou (CR16) 2009; 2 Vitellaro-Zuccarello, Mazzetti, Madaschi (CR10) 2008; 151 Okutan, Solaroglu, Beskonakli (CR6) 2007; 14 Liu, Suzuki, Guo (CR2) 2006; 96 Gorio, Madaschi, Di Stefano (CR14) 2005; 102 Capaul, Zollinger, Satz (CR3) 1994; 32 W.S. EI Masry (576_CR4) 1996; 21 O. Okutan (576_CR6) 2007; 14 X.Q. Fang (576_CR11) 2009; 122 M. Xiong (576_CR17) 2011; 28 R. Liu (576_CR2) 2006; 96 C. Dame (576_CR1) 2001; 79 G. Grasso (576_CR5) 2007; 20 K. Maiese (576_CR16) 2009; 2 L. Vitellaro-Zuccarello (576_CR8) 2007; 144 G.K. Matis (576_CR12) 2009; 18 V.A. Kontogeorgakos (576_CR13) 2009; 129 M. Capaul (576_CR3) 1994; 32 B.H. Choi (576_CR7) 2007; 412 A. Gorio (576_CR14) 2005; 102 L. Vitellaro-Zuccarello (576_CR10) 2008; 151 C. Mann (576_CR9) 2008; 211 M.S. Kim (576_CR15) 2010; 53 7997337 - Paraplegia. 1994 Sep;32(9):583-7 8852318 - Spine (Phila Pa 1976). 1996 Mar 1;21(5):614-9 19719963 - Chin Med J (Engl). 2009 Jul 20;122(14):1631-5 17878959 - Drug News Perspect. 2007 Jun;20(5):315-20 18313052 - Exp Neurol. 2008 May;211(1):34-40 18309506 - Arch Orthop Trauma Surg. 2009 Feb;129(2):189-94 17236773 - J Clin Neurosci. 2007 Apr;14(4):364-8 17178192 - Neurosci Lett. 2007 Jan 29;412(2):118-22 20716915 - Oxid Med Cell Longev. 2009 Nov-Dec;2(5):279-89 17141961 - Neuroscience. 2007 Feb 9;144(3):865-77 19030901 - Eur Spine J. 2009 Mar;18(3):314-23 11275657 - Biol Neonate. 2001;79(3-4):228-35 21189961 - Korean J Pediatr. 2010 Oct;53(10):898-908 16260722 - Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16379-84 16417583 - J Neurochem. 2006 Feb;96(4):1101-10 18065151 - Neuroscience. 2008 Jan 24;151(2):452-66 |
| References_xml | – volume: 96 start-page: 1101 issue: 4 year: 2006 end-page: 1110 ident: CR2 article-title: Intrinsic and extrinsic ery thropoietin enhances neuroprotection against ischemia and reperfusion injury publication-title: J Neurochem doi: 10.1111/j.1471-4159.2005.03597.x – volume: 211 start-page: 34 issue: 1 year: 2008 end-page: 40 ident: CR9 article-title: Delayed treatment of spinal cord injury with erythropoietin or darbepoetin—a lack of neuroprotective efficacy in a contusion model of cord injury publication-title: Exp Neurol doi: 10.1016/j.expneurol.2007.12.013 – volume: 20 start-page: 315 issue: 5 year: 2007 end-page: 320 ident: CR5 article-title: The role of erythropoietin in neuroprotection: therapeutic perspectives publication-title: Drug News Perspect doi: 10.1358/dnp.2007.20.5.1120219 – volume: 32 start-page: 583 issue: 9 year: 1994 end-page: 587 ident: CR3 article-title: Analyses of 94 consecutive spinal cord injury patients using ASIA definition and modified Frankel score classification publication-title: Paraplegia doi: 10.1038/sc.1994.92 – volume: 122 start-page: 1631 issue: 14 year: 2009 end-page: 1635 ident: CR11 article-title: Protection of erythropoietin on experimental spinal cord injury by reducing the expression of thrombospondin-1 and transforming growth factor-beta publication-title: Chin Med J (Engl) – volume: 28 start-page: 618 issue: 4 year: 2011 end-page: 520 ident: CR17 article-title: The effect of erythropoietin on the mobility of bone marrow mesenchymal stem cell to the sites of injured spinal cord publication-title: Chin J Exp Surg (Chinese) – volume: 79 start-page: 228 issue: 3–4 year: 2001 end-page: 235 ident: CR1 article-title: The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential publication-title: Biol Neonate – volume: 151 start-page: 452 issue: 2 year: 2008 end-page: 466 ident: CR10 article-title: Chronic erythropoietin-mediated effects on the expression of astrocyte markers in a rat model of contusive spinal cord injury publication-title: Neuroscience doi: 10.1016/j.neuroscience.2007.11.004 – volume: 53 start-page: 898 issue: 10 year: 2010 end-page: 908 ident: CR15 article-title: The neuroprotective effect of recombinant human erythropoietin via an antiapoptotic mechanism on hypoxic-ischemic brain injury in neonatal rats publication-title: Korean J Pediatr doi: 10.3345/kjp.2010.53.10.898 – volume: 2 start-page: 279 issue: 5 year: 2009 end-page: 289 ident: CR16 article-title: New strategies for Alzheimer’s disease and cognitive impairment publication-title: Oxid Med Cell Longev doi: 10.4161/oxim.2.5.9990 – volume: 21 start-page: 614 issue: 5 year: 1996 end-page: 619 ident: CR4 article-title: Validation of the American Spinal Injury Association (ASIA) motor score and the National Acute Spinal Cord Injury Study (NASCIS) motor score publication-title: Spine doi: 10.1097/00007632-199603010-00015 – volume: 129 start-page: 189 issue: 2 year: 2009 end-page: 194 ident: CR13 article-title: The efficacy of erythropoietin on acute spinal cord injury. An experimental study on a rat model publication-title: Arch Orthop Trauma Surg doi: 10.1007/s00402-008-0594-x – volume: 144 start-page: 865 issue: 3 year: 2007 end-page: 877 ident: CR8 article-title: Erythropoietin-mediated preservation of the white matter in rat spinal cord injury publication-title: Neuroscience doi: 10.1016/j.neuroscience.2006.10.023 – volume: 14 start-page: 364 issue: 4 year: 2007 end-page: 368 ident: CR6 article-title: Recombinant human erythropoietin decreases myeloperoxidase and caspase-3 activity and improves early functional results after spinal cord injury in rats publication-title: J Clin Neurosci doi: 10.1016/j.jocn.2006.01.022 – volume: 18 start-page: 314 issue: 3 year: 2009 end-page: 323 ident: CR12 article-title: Erythropoietin in spinal cord injury publication-title: Eur Spine J doi: 10.1007/s00586-008-0829-0 – volume: 102 start-page: 16 379 issue: 45 year: 2005 end-page: 16 384 ident: CR14 article-title: Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0508479102 – volume: 412 start-page: 118 issue: 2 year: 2007 end-page: 122 ident: CR7 article-title: A hypoxia-inducible gene expression system using erythropoietin 3′ untranslated region for the gene therapy of rat spinal cord injury publication-title: Neurosci Lett doi: 10.1016/j.neulet.2006.11.015 – volume: 412 start-page: 118 issue: 2 year: 2007 ident: 576_CR7 publication-title: Neurosci Lett doi: 10.1016/j.neulet.2006.11.015 – volume: 211 start-page: 34 issue: 1 year: 2008 ident: 576_CR9 publication-title: Exp Neurol doi: 10.1016/j.expneurol.2007.12.013 – volume: 14 start-page: 364 issue: 4 year: 2007 ident: 576_CR6 publication-title: J Clin Neurosci doi: 10.1016/j.jocn.2006.01.022 – volume: 129 start-page: 189 issue: 2 year: 2009 ident: 576_CR13 publication-title: Arch Orthop Trauma Surg doi: 10.1007/s00402-008-0594-x – volume: 20 start-page: 315 issue: 5 year: 2007 ident: 576_CR5 publication-title: Drug News Perspect doi: 10.1358/dnp.2007.20.5.1120219 – volume: 151 start-page: 452 issue: 2 year: 2008 ident: 576_CR10 publication-title: Neuroscience doi: 10.1016/j.neuroscience.2007.11.004 – volume: 28 start-page: 618 issue: 4 year: 2011 ident: 576_CR17 publication-title: Chin J Exp Surg (Chinese) – volume: 144 start-page: 865 issue: 3 year: 2007 ident: 576_CR8 publication-title: Neuroscience doi: 10.1016/j.neuroscience.2006.10.023 – volume: 18 start-page: 314 issue: 3 year: 2009 ident: 576_CR12 publication-title: Eur Spine J doi: 10.1007/s00586-008-0829-0 – volume: 79 start-page: 228 issue: 3–4 year: 2001 ident: 576_CR1 publication-title: Biol Neonate – volume: 32 start-page: 583 issue: 9 year: 1994 ident: 576_CR3 publication-title: Paraplegia doi: 10.1038/sc.1994.92 – volume: 96 start-page: 1101 issue: 4 year: 2006 ident: 576_CR2 publication-title: J Neurochem doi: 10.1111/j.1471-4159.2005.03597.x – volume: 122 start-page: 1631 issue: 14 year: 2009 ident: 576_CR11 publication-title: Chin Med J (Engl) – volume: 21 start-page: 614 issue: 5 year: 1996 ident: 576_CR4 publication-title: Spine doi: 10.1097/00007632-199603010-00015 – volume: 102 start-page: 16 379 issue: 45 year: 2005 ident: 576_CR14 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0508479102 – volume: 53 start-page: 898 issue: 10 year: 2010 ident: 576_CR15 publication-title: Korean J Pediatr doi: 10.3345/kjp.2010.53.10.898 – volume: 2 start-page: 279 issue: 5 year: 2009 ident: 576_CR16 publication-title: Oxid Med Cell Longev doi: 10.4161/oxim.2.5.9990 – reference: 17236773 - J Clin Neurosci. 2007 Apr;14(4):364-8 – reference: 20716915 - Oxid Med Cell Longev. 2009 Nov-Dec;2(5):279-89 – reference: 16260722 - Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16379-84 – reference: 18313052 - Exp Neurol. 2008 May;211(1):34-40 – reference: 8852318 - Spine (Phila Pa 1976). 1996 Mar 1;21(5):614-9 – reference: 7997337 - Paraplegia. 1994 Sep;32(9):583-7 – reference: 21189961 - Korean J Pediatr. 2010 Oct;53(10):898-908 – reference: 18309506 - Arch Orthop Trauma Surg. 2009 Feb;129(2):189-94 – reference: 17878959 - Drug News Perspect. 2007 Jun;20(5):315-20 – reference: 19030901 - Eur Spine J. 2009 Mar;18(3):314-23 – reference: 16417583 - J Neurochem. 2006 Feb;96(4):1101-10 – reference: 18065151 - Neuroscience. 2008 Jan 24;151(2):452-66 – reference: 17178192 - Neurosci Lett. 2007 Jan 29;412(2):118-22 – reference: 19719963 - Chin Med J (Engl). 2009 Jul 20;122(14):1631-5 – reference: 11275657 - Biol Neonate. 2001;79(3-4):228-35 – reference: 17141961 - Neuroscience. 2007 Feb 9;144(3):865-77 |
| SSID | ssj0057624 |
| Score | 1.5815035 |
| Snippet | Recent research based on various animal models has shown the neuroprotective effects of erythropoietin （EPO）. However, few studies have examined such effects... Summary Recent research based on various animal models has shown the neuroprotective effects of erythropoietin (EPO). However, few studies have examined such... Recent research based on various animal models has shown the neuroprotective effects of erythropoietin (EPO). However, few studies have examined such effects... |
| SourceID | proquest pubmed crossref springer chongqing |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 652 |
| SubjectTerms | Activities of daily living Adult Aged Animal models Decompression, Surgical - adverse effects Erythropoietin Erythropoietin - therapeutic use Female Humans Male Medicine Medicine & Public Health methylprednisolone Methylprednisolone - therapeutic use Middle Aged Neuroprotection Neuroprotective Agents - therapeutic use Reperfusion Injury - prevention & control Retrospective Studies Spinal Cord - surgery Spinal Cord Compression - surgery Spinal cord injury Spinal Cord Ischemia - etiology Therapeutic applications 临床应用 促红细胞生成素 尼龙 神经保护作用 神经功能 缺血再灌注损伤 脊髓损伤 蒙特利尔议定书 |
| Title | Neuroprotection of Erythropoietin and Methylprednisolone against Spinal Cord Ischemia-Reperfusion Injury |
| URI | http://lib.cqvip.com/qk/85740A/201105/40176062.html https://link.springer.com/article/10.1007/s11596-011-0576-z https://www.ncbi.nlm.nih.gov/pubmed/22038355 https://www.proquest.com/docview/1285091358 https://www.proquest.com/docview/901308011 |
| Volume | 31 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAVX databaseName: SpringerLINK - Czech Republic Consortium customDbUrl: eissn: 1993-1352 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0057624 issn: 1672-0733 databaseCode: AGYKE dateStart: 19970101 isFulltext: true titleUrlDefault: http://link.springer.com providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerLink Journals (ICM) customDbUrl: eissn: 1993-1352 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0057624 issn: 1672-0733 databaseCode: U2A dateStart: 20020101 isFulltext: true titleUrlDefault: http://www.springerlink.com/journals/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LT9wwEB7BIlW90Ja-AgUZqSeqoHXePq4QDxXREyvRk-XHBEJpdsnuHthf3_EmXlReEsoxjuN4xjPfl7FnAL5bkZLdt1moeWHCRCMPRWQ5CSS3ZY66TI07jXz2KzsZJj8v0ovuHPfE73b3IcmFpb4_7Eae17Ffor8EksP5Kqwt0m31YG1w_Pv00BtgutnWss1yt7Eyjn0w86lOXEqFq1F9eUsv_N81PcKbj2KlCxd09A7O_eDbnSd_9mdTvW_mD_I6vvLr3sN6B0nZoNWhD7CC9Qa8OeuC7h_hapHAo0voQGJko5Jhc9cWWKjckWmmastcLeq7m3GDtq5IoUc1MnWpKoKfbDJ2tbeYI7qsIjqNfysVNjjGppy5v3Wsqq9Jtp9geHR4fnASdgUaQkO0cxqi0lyXPDcEIoXNC2u4VkZYTLTQtLYxLRBznRYKS81FkRnMhE1UXxuekArHn6FX03C-AouNzrgh8mSc8pSO5ihiUpGhywqeBLC5lJMct4k4JHHDnAhYFEDfC06aLrW5q7BxI--TMrvplTS90k2vnAewt3zEd_dC412vDZJWnwupqBpHs4kk7-4QV5wWAbBn2ggXHCYgwAP40mrS8o1R1I8JAqcB_PBaITsbMnl-OJuvar0FbyO_b5F_g960meE2Aamp3ukWzg6sDqPBP_GzGI4 |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB5BkaAXxJsUCkbiBIq0ztvHClFtodtTV-rN8mPSpirZJbt7aH99ZzbxVqgPCeUYx7b8jT3zZTwzAF-9yunc90VsZeXizKKMVeIlAVL6ukRb546jkSdHxXia_TrJT4Y47kW47R5ckuuT-ibYjTQvs1-iv2Qkx1eP4Qnnr-KE-dNkLxy_9KqvZFuUfK0yTYMr864uOKHC2aw9_UvD_auYblmbtzylawW0_wKeD5aj2OuhfgmPsH0FTyeDb_w1nK3zbAx5F2i1xawW2F32dRAajmwWpvWCS0ZfXsw79G1DcjdrUZhT05CVKBZzLpElmI-Khlgv_mlM3OEcu3rFP9VE054TBG9guv_z-Mc4HuooxI7Y4TJGY6WtZenI1lO-rLyT1jjlMbPK0hbEvEIsbV4ZrK1UVeGwUD4zI-tkRpKWvoWtlqbzHkTqbCEdcRzHGNfMRgwRnsTR45XMItjZLKie9_kyNFG4knhSEsEorLB2QwZyLoRxoW9yJzNAmgDSDJC-iuDb5pPQ3QONvwTYNG0S9nyYFmerhSYlzIZRmlcRiHvaKPbhkr6WEbzrId-MmCQjIvJ5HsH3IAN62OqL-6ez81-tP8Oz8fHkUB8eHP3-ANtJuGooP8LWslvhLtk-S_tpLevX-Wf9ag |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB5BkSouqLzT8jASJ1DUdd4-VsCqPFpxYKXeLD8mbariDdndQ_vrmdkkW6FSJJRjHNvyN_bMl_HMALz1Kqdz3xexlZWLM4syVomXBEjp6xJtnTuORj46Lg5n2ZeT_GSoc7oYb7uPLsk-poGzNIXlfuvr_evAN9LCzISJCpPBHF_dhXsZ50kggZ4lB-NRTK_6qrZFyVcs03R0a_6tC06ucDYPp79o6D-V1A3L84bXdK2MpjvwYLAixUEP-0O4g-ERbB8NfvLHcLbOuTHkYKCVF_NaYHfZ10RoOMpZmOAFl4--vGg79KEhGZwHFObUNGQxikXL5bIEc1PREAPGn42JO2yxq1f8g0004ZzgeAKz6acfHw7joaZC7IgpLmM0Vtpalo7sPuXLyjtpjVMeM6ssbUfMK8TS5pXB2kpVFQ4L5TMzsU5mJHXpU9gKNJ3nIFJnC-mI7zjGu2ZmYoj8JI4er2QWwe5mQXXb587QROdK4kxJBJNxhbUbspFzUYwLfZ1HmQHSBJBmgPRVBO82n4zd_aPxmxE2TRuGvSAm4Hy10KSQ2UhK8yoCcUsbxf5c0t0ygmc95JsRk2RCpD7PI3g_yoAetv3i9uns_lfr17D9_eNUf_t8_HUP7ifjrUP5AraW3Qpfkhm0tK_Wov4bRNQBtQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Neuroprotection+of+erythropoietin+and+methylprednisolone+against+spinal+cord+ischemia-reperfusion+injury&rft.jtitle=Journal+of+Huazhong+University+of+Science+and+Technology.+Medical+sciences&rft.au=Xiong%2C+Min&rft.au=Chen%2C+Sen&rft.au=Yu%2C+Hualong&rft.au=Liu%2C+Zhigang&rft.date=2011-10-01&rft.pub=Huazhong+University+of+Science+and+Technology&rft.issn=1672-0733&rft.eissn=1993-1352&rft.volume=31&rft.issue=5&rft_id=info:doi/10.1007%2Fs11596-011-0576-z&rft.externalDocID=10_1007_s11596_011_0576_z |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F85740A%2F85740A.jpg |